Speaker

Speaker Introduction

Kaixian Chen
Chinese Academy of Sciences
Academician

Subject
Sperm-like Stem Cell-mediated Genome Editing

Jinsong Li
CAS Center for Excellence in Molecular Cell Science,Shanghai Institute of Biochemistry and Cell Biology(SIBCB), Chinese Academy of Science
Director, State Key Laboratory of Cell Biology

Subject
Synthetic Immunology and NK Cell Therapy

Zhigang Tian
Chinese Academy of Engineering, University of Science and Technology of China
Academician, Director of the Institute of Immunology

Zhihong Xu
Chinese Academy of Sciences
Academician

Subject
Research on Innovative Drugs: The Biological Principles of Treating Diseases Via Both Symptoms & Root Causes

Jiandong Jiang
Chinese Academy of Engineering, Institute of PharmaceuticalResearch, CAMS & PUMC
Academician,Head

Subject
Stereocontrolled Total Synthesis of Prostaglandin Family—From Chiral Auxiliary Induction to Asymmetric Catalysis

Fener Chen
Chinese Academy of Engineering, Fudan University
Academician, Professor

Ning Gu
Chinese Academy of Sciences, Nanjing University
Academician, Professor

Subject
口腔微生物组——口腔细菌在口腔外感染和炎症中的作用

Yiping W. Han
American Academy of Microbiology / Columbia University
Fellow /Professor

Subject
Innovation and Partnership to Advance global Health by Creating New Market

Fujie Xu
Bill & Melinda Gates Foundation
Deputy Director, Health, Innovation and Partnership, China Country Office

Subject
“Green by Design (GbD)” Principal as a Reliable Navigator of Environmental Sustainability in Modern Pharmaceutical Industry

Xiangdong Feng

Subject
Oriented to clinical value, make first-class Chinese independent innovative drugs

Weiguo Su
HUTCHMED
Chief Executive Officer and Chief Scientific Officer, HUTCHMED

Subject
推动生物医药领域创新的技术发展趋势

Garry Neil
Avalo Therapeutics
President & Chief Executive Officer

Subject
Precise Visual-diagnosis and Treatment of Senescence / Aging

Jian Li
East China University of Science & Technology
Vice President, Professor

Subject
Whole-cell digital twin and metaverse

Zhixing Cao
East China University of Science and Technology
Professor, Doctoral Supervisor

Subject
Pre-diagnosis of Mental Disorders Using iPSC Technology

Lingsong Li
RJK- Biopharm INC.
Company founder and Chairman

Subject
Pharmapheutic Applications Targeting Innate Immunity

Fajian Hou
Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences
Principal Investigator

Subject
The Construction of Human Genetic Resources Management System in China

Min Zhu
China National Center for Biotechnology Development
Deputy Director of Biological Resources and Safety Division

Subject
Local Regulatory Policies of Drugs for CAR-T Cell Therapy: Research and Practice

Lan Shi
Shanghai Medical Products Administration
Director of Drug Administration Division

Xiangyu Li
Shanghai Center for Drug Evaluation and Inspection
Deputy Director

Jingchen Zhang
Shanghai Center for Drug Evaluation and Inspection
Deputy Director

Subject
Regulatory Considerations for mRNA Vaccines

Meng Cao
Shanghai Center for Drug Evaluation and Inspection
Deputy Head of Innovation and Regulatory Science Dept.

Subject
siRNA in Clinical Development for HBV Functional Cure

Xiaofei Chen
Briibiosciences
Senior Director ,Clinical research

Subject
Bacterial Vector Gene Therapy

Bin Xiang
CommBio Therapeutics Co., Ltd.
Founder and CEO

Subject
Drug Good Regulatory Practice (GRP) and Lifecycle Pharmacovigilance System

Guangping Wang
Shanghai Center for Adverse Drug and Medical Device Reaction Monitoring
Policy Researcher

Subject
mRNA and Medicine: COVID-19, Omicron and Beyond

Aimin Hui
SharpSight Biopharma Consulting
General Manager

Subject
mRNA Translational Research

Jinzhong Lin
Fudan University
Professor

Subject
The Significance of Independent Data Safety Management in Vaccine Clinical Trials

Jielai Xia

Jia Liu

Subject
Clinical Quality Management System (cQMS)

Hua Chen

Subject
What We could Learn from Approved CAR-T Cell Therapy Products to Develop Our Own Ones

Thomas Jaw
Virginia Contract Research Organization (Shanghai) Co., Ltd.
Vice President

George Siber

Subject
Engineering design of mRNA-based medicines and innovative application of domestic equipment

Mingda Li

Shaoxiong Chen
Shanghai Biopharmaceutics Industry Association (SBIA)
Executive Chairman and Secretary-General

Fei Huang
HRAIN BIOTECHNOLOGY
General Manager

Subject
Independent R&D for IVD Enterprises: Difficulties and Ways Out

Qingui Bao
Shanghai Fosun Long March Medical Science Co.,Ltd (Medical Diagnosis Division of Shanghai Fosun Pharmaceutical(Group)Co., Ltd)
Fosun Global Partner, Senior Vice President of Fosun Pharma,Chairman of Medical Diagnosis Division

Lingli Yu
Shanghai Center for Drug Evaluation and Inspection
Senior Drug Reviewr

Baozhu Yuan
(Shanghai)QS-Bio Inc;Tongji University
President/CEO/CSO;Professor

Liming Shao

Subject
Research Progress on iPSC-CAR-NK

Liqun Wang
Neukio Biotherapeutics
CEO

Subject
The Value of Innovative Drugs: Co-building an Innovation Ecosystem

Hai Huang
FosunKite Biotechnology Co., Ltd.
CEO

Subject
Frontier Technology and Application of Cell Therapy

Minmin Sun
Shanghai Immuno Biotech Co., Ltd.
Founder, Chairman, CEO

Subject
ATMP for Longevity

Guangqian Zhou
The Center for Anti-aging and Regenerative Medcine
Director, Professor

Subject
Microbial Production of Human Milk Oligosaccharides (HMOs) in China, an Industry on the Horn of a Dilemma?

Junsong Sun
Shanghai Advanced Research Institute, CAS
Professor

Subject
Development of an Ovarian Cancer Screening System

Yuefei Yu
Shanghai Huitai Biotech Co., LTD
Chief scientist

Subject
Biobased Production of Drugs to Fight Malaria

Chou Howard
Shenzhen Institute of Advanced Technology, CAS
Senior Engineer

Subject
Strategies for Building a Sustainable Bioinnovation Ecosystem for the 21st Century

Kenneth I. Kaitin
Tufts University School of Medicine, Tufts Center for the Study of Drug Development
Professor, Former Director

Jun Meng
Origincell Technology Group Corporation
Vice President

Subject
The Development of CAR-T Cells from the Clinical View

Zonghai Li
CARsgen Therapeutics Co., Ltd.
Chairman, CEO, CSO

Subject
Practice and Prospect of Regional Research Ethics Collaboration Platform (Nanjing)

Xiuqin Wang
First Affiliated Hospital with Nanjing Medical University
Director, Department of International Cooperation

Subject
Key Points of Human Genetic Resources Project Evaluation

Ronghua Jin
Beijing Ditan Hospital, Capital Medical University
Dean

Subject
The Innovation-driven Development of Medicine in the Yangtze River Delta: Outlook and Reflections

Jingkang Shen
Shanghai Institute of MateriaMedica,Chinese Academy of Sciences
Researcher

Huiming Zhang
The Enterprise Research Institute of Fudan University,The Yangtze River Delta Research Institute of Fudan University

Subject
Promote Clinical Trial Cooperation in the Yangtze River Delta Region, Accelerate the High-Quality Development of the Biomedical Industry

Jun Zhao
First Affiliated Hospital with Nanjing Medical University
President

Subject
Mechanism for Collaborative Clinical Trials by the Clinical Trial Sites Adhering to GCP in the Yangtze River Delta

Guoying Cao
Huashan Hospital Fudan University
Director of the Office of Drug Clinical Trials

Mingde Xia
Innolake Biopharm
Founder, Chairman, and CEO

Xiaonan Zheng
China Biomedical Industry Chain Innovation and Transformation Alliance
Executive Vice Director and Secretary-General

Subject
Global Frontier Separation and Purification Technologies for Biomedicine and Their Development Trends

BIWANG JACK JIANG
Suzhou Nanomicro Technology Co., Ltd.
Chairman

Subject
Innovation, Quality and Efficiency — Yangtze River Delta Biopharmaceutical Innovation Development Forum 2022

Wensong Tan
Shanghai BioEngine Sci-Tech Co., Ltd
Chairman

Subject
Regulatory Requirement and Case Study on Human Genetic Resources

Yang Gu
Han Kun Law Offices
Partner

Zhaolong Gong
3D Medicines Inc.

Hao Li
Pharmaron Beijing Co., Ltd.
Clinical Chief Medical Officer

Subject
Research Progress on Immunotherapy of Atherosclerosis

Dianwen Ju
Fudan Universty
Head of Biomedicines Dept, School of Pharmacy

Wengui Weng

Guodong Jia
OBiO Technology (Shanghai) Corp., Ltd.
General Manager

Angen Yuan
Tenykin, Yangtze River Delta Pharmaceutical Innovation and Development Alliance
Founder&Chairman、Vice Director and Secretary-General

Qing Yang
Professional Committee of Biochemical and Biotechnological Drug, Shanghai Pharmaceutical Association, Fudan University
Deputy Director Member, Professor

Subject
Design and Development of Novel Antibody-cytokine Fusion Proteins Based on IL-15

Huili Lu
Shanghai Jiao Tong University
Associate Research Fellow, School of Pharmacy

Subject
Frontier Technologies for Core Enzyme Raw Materials for Biological Drugs and their Development Trends

Guangyu Yang
HZYMES Bio-tech Co., Ltd.
Chairman

Changchun Zha
Biointron Biological Inc.
Founder & Chairman

Wenzheng Jiang
Professional Committee of Biochemical and Biotechnological Drug, Shanghai Pharmaceutical Association, East China Normal University
Director, Associate Dean, Professor

Subject
Industrialization Research of Nanobody

Yakun Wan
Shanghai Institute of Materia Medica, ChineseAcademy of Sciences Shanghai Novamab Biopharmaceuticals Co., Ltd.
Professor, CEO

Subject
Discovery of Antibody Biological Drugs in Preclinical Phases

Wenxiang Zhao
Shanghai SYMRAY Biopharma Co., Ltd.
Chief Executive Officer

Shaoping Cao
Shanghai Medical Association Clinical Engineering Branch
Former Director

Subject
Interpretation of the Validation Technical Requirements for Rapid Sterility Testing Method of Cellular and Gene Therapy Products

Yan Yang
Shanghai Institute for Food and Drug Control
Study director

Jianguo Qian
Shanghai Medical Association Clinical Engineering Branch
Former Director

Shuang Chen
Shanghai Medical Association Clinical Engineering Branch, HuaShan Hospital Fudan University
Director

Subject
Current Situation of Medical Equipment Industry and Interpretation of the 14th Five Year Plan

Bin Li
Clinical Engineering Society of Chinese Medical Association, Shanghai Sixth People's Hospital Affiliated to Jiaotong University
Chairma

Subject
Designated Hospital and Mobile Lab-improving the Lab Competency in COVID-19 Prevention and Treatment

Ming Guan
Huashan Hospital Fudan University
Director of Clinical Laboratory

Feng Ni
Shanghai Shyndec Pharmaceutical Co.,Ltd.
Headmaster of Shyndec Research Institute of Sinopharm

Subject
A New CBDTM Model of Clinical Translational Medicine Undergoing the Baptism of the War of Covid-19

Hengjun Gao
National Engineering Center for Biochips at Shanghai
Director

Subject
COVID-19 Transmission and Hospitals’ Prevention and Control Measures

Erzhen Chen
Ruijin Hospital
Deputy Dean

Subject
The Role of Robots in Fighting the Epidemic

Jing Pan
Shanghai TMI Robotics Technology Co.,Ltd
Chairman & CEO

Subject
Take the prevention and control of COVID-19 as an opportunity to promote the development of disinfection technology

Liang Tian
Shanghai Municipal Center For Disease Control and Prevention
Chief Physicians

Subject
Industrial Application of Green Fluorine Technology (GFT) in Pharmaceuticals

Fanhong Wu
Shanghai Institute of Technology, Shanghai Green Fluorine Pharmaceutical Engineering Technology Research Center
Professor, Director

Subject
Angle Control and Synergistic Promotion Strategies in Asymmetric Synthesis of Chiral Pharmaceuticals

Wanbin Zhang
Shanghai Jiao Tong University, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs
Chair Professor, Director

Subject
Industrial Application of Pharmaceutical Innovation Process

Guan Wang
Professor of Shanghai Institute of Pharmaceutical Industry, joint postgraduate tutor of Shanghai Jiao Tong University and Shanghai University of Engineering Technology

Subject
Host Defense Peptide Mimicking Peptide Polymers Displaying Potent Activity against Drug-Resistant Microbes

Runhui Liu
East China University of Science and Technology Professor

Subject
R&D strategy on modified paediatric drugs

Dunwei Guo
HQ Pharma
Founder and CEO

Subject
Development and Opportunities of Synthetic Biology from the Perspective of Investment

Jie Wu
Shanghai Science Venture Capital & Technology Investment Co., Ltd
Vice General Manager

Yongfeng Yu

Subject
Application and Development of Circular RNA Technology

Yun Yang
Shanghai Circode Biomed Co.,Ltd
Cofounder and CTO

Subject
R&D Strategy on Modified Paediatric Drugs

Dunwei He
HQ Pharma
Founder and CEO

Subject
Opportunities and Adjustments for Hong Kong Biotech Listed Companies under Rule 18A

Xiaocheng Yang
Frost & Sullivan
Partner

Subject
The Construction of Oligonucleotide Therapeutics with Artificial Base

Ruowen Wang
Shanghai Jiao Tong University School of Medicine
Professor

Subject
CRISPR Technology in the Diagnosis of Pathogens

Baihui Zhao
Shanghai BioGerm Medical Technology Co., Ltd.
Company Founder and General Manager

Xia Qu
Shanghai Lingang Lanwan Private Equity Fund Management Co., Ltd.
CEO

Subject
Create Biocatalysts and Cell Factories, Promote Green Biological Manufacturing under the Vision of "Carbon Reduction"

Dongzhi Wei
East China University of Science and Technology
Professor

Subject
Process and Analytical Development for Bispecific Antibodies: Challenges and Solutions

Gang Huang
Biologics Development, WuXi Biologics
Senior Vice President

Subject
Genetic Testing and Reproductive Health

Sijia Lu
Yikon Genomics (Shanghai) Co., Ltd.
President and CEO

Lei Yu
Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
CTO

Dandan Chen
Shanghai Institute of Biological Products
Deputy Manager of R&D Department & Director of Clinical Research Office

Subject
Frontiers and key technologies of nucleic acid drug

Kun Cai
Hongene Biotech Corporation
Director of Medical Department

Subject
Experience of Industry-university-research Integration Construction

Juahua Zeng
Henan Tuoren Medical Device Co., Ltd
Vice President, Marketing Headquarters and Director of Academic Department

Subject
Critical Quality Control Items and Detection Technologies for mRNA Vaccines

Ziqiang Wang
Shanghai Institute for Food and Drug Control
Inspectors

Subject
A mRNA Vaccine for Omicron Variant

Weiguo Jia
CNBG-Virogin Biotech (Shanghai) Co.,Ltd.
Chief Scientific Officer

Subject
How Clinical Development Plan Could Make a Vaccine Competitive

Yuan Yuan
PATH
China Country Representative, Business & Commercialization Lead

Subject
The Role of the Real-world Data in Vaccine Safety Evaluation

Yang Feng
Xiamen Chazen Biomedical Technology Company
General Manager

Subject
Standardizing and Inspection the Quality and Safety of Cell Products is the Prerequisite for the Healthy Development of Shanghai's Cell Therapy Industry

Liping Gu
Shanghai Precise Inspection Co., Ltd.
General Manager

Zhen Lu
Shanghai Municipal Education Commission Science & Technology Development Center
Director

Daxu Fu

Jianliang Deng

Weihao Jiang
Shanghai BioScience Co., Ltd.
Director

Jizong Li
Shanghai Center of Biomedicine Development
Director

Subject
Introduction to the Pilot Service Platform for Antibody Drugs

Dawei Ren
Shanghai Center of Biomedicine Development
Deputy Director, Professor

Subject
Deepening the IVD-SPD Service Model in Post-epidemic Era and Creating a High-quality Material Supply System

Yu Yang
Sinopharm Runda Medical Supply Chain Services(Shanghai) Co,. Ltd.
General Manager

Subject
Enzyme Engineering Creates Green Antibiotic Industry

Chungang Li
Shanghai Shyndec Pharmaceutical Co.,Ltd.
Vice President of Shyndec Research Institute of Sinopharm

Subject
Improvement and Innovation Based on Drug Crystal Engineering Technology

Guobin Ren
Institute of Science and Technology Development, East China University of Science and Technology
Associate Dean, Distinguished Professor

Subject
Ethical and Social Issues and Regulations on HGR Governance and Relevant Case Study Analysis

Yajun Yang
School of Life Sciences, Fudan University
Professor

Subject
Common Problems in Field Inspection of Human Genetic Resource Management

Xuening Li
Zhongshan Hospital, Fudan University
Head of GCP Office

Subject
The Third Tide in Modern Pharmaceuticals: Prime Time for Small Nucleic Acid Pharmaceuticals

Zicai Liang
Suzhou Ribo Life Science Co. Ltd.
Chairman&CEO

Subject
Large Scale Manufacture and Quality Control Strategy for mRNA plasmids

Ping Zou
WuXi Advanced Therapies
Head & Executive Director of Production Department and Lingang Base

Meng Fu
Redbud Medicine
Founder, CEO

Xiaoyan Zhang
National Engineering Center for Biochip at Shanghai
Head of Biobank

Rong Ji
Becton, Dickinson and Company
Associate Sales Director

Subject
Advanced Flow Photo Reactor Technology Empowers Innovative R&D of Pharmaceutical

Xinjun Wu
Corning Advanced Flow Reactor Technology Co., Ltd.
Director of Corning AFR Academy, Corning Reactor Technology Center (China)

Subject
From Bench to Bedside: Delivering Precision Oncology in a Clinical Setting

Aya EL HELALI
The University of Hong Kong
Clinical Assistant Professor, Department of Clinical Oncology, School of Clinical Medicine

Subject
Exploration and practice of CanSino Biotechnology in the field of mRNA Technology

Jian Liu
CanSino Biologics(Shanghai)Co., Ltd
General Manager

Subject
Statistical Considerations in the Clinical Development of Innovative Vaccines

Zhiwei Jiang
Beijing KeyTech Statistical Consulting Co., Ltd
General Manager

Xuanyi Wang

Subject
Application of Pseudtyped Virus Technology in Virus Mutation Research and Vaccine Evaluation

Weijin Huang
National Institutes for Food and Drug Control(NIFDC)
Director of Division of HIV/AIDS and sex-transmitted virus vaccines

Rulei Chen

Jingwen Ai

Jing Jiang
PATH
Consultant

Chen Yao

Jian Hou
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Head of Hematology Dept.

Cong Wang
Shanghai International Medical Zone Group
Deputy General Manager

Subject
Exploring New Mechanisms of Research and Review Linkage to Facilitate the Innovation-driven Development of Medicine in the Yangtze River Delta

Jinbo Yang
Yangtze River Delta Sub-center for Drug Evaluation and Inspection, National Medical Products Administration
Director

Naxin Ji
Vice President and China Head of Development in GSK

Subject
Engineering Design of mRNA-based Drugs and Innovative Application of Chinese-made Devices

Junhua Yu

Subject
Scientific Investigation and Data Publication of Vaccine Clinical Trials

Ting Wu
Xiamen University,National Institute of Diagnosis and Vaccine Development in Infectious Diseases
Professor,Leader of Clinical Research Team

Subject
Selection and Management of the Laboratory Center for Vaccine Clinical Trials

shangying Hu
Cancer Hospital Chinese Academy of Medical Sciences
Associate Professor

Subject
Controlled Human Infection Modelling

Andrew Catchpole
hVIVO
Chief Scientific Officer

Subject
New Strategies of Lymphoma Targeted Therapy in the Era of Translational Medicine

Weili Zhao
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Deputy Director of Hospital

Lifang Zhang
Shanghai Medical Association Clinical Engineering Branch
Honorary Director Member

Subject
Application Analysis of COVID-19 Tests (NAAT and Antigen Test) in Different Pandemic Scenarios

Min Chen
Shanghai Municipal Center for Disease Control & Prevention
Vice Director

Subject
The Process Research and Development for VV116 API

Jingshan Shen
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Professor

Subject
Smart Manufacturing and Application of Novel Proteins

Li Liao
Shanghai Changin Biotechnology Co., Ltd.
CTO

Rongcheng Li
GuangXi Center for Disease Prevention and Control
Former Director of the Institute

Subject
Application of Green Technology in Pharmaceutical Field

Jianguo Ma
Zhejiang Langhua Pharmaceutical Co., Ltd.
Chief Executive Officer

Subject
Opportunities and challenges for CDMO in China

Dan Xu
3S Pharmaceutical Group
Associate Director of BD

Bangwei Yu
Shanghai Zerun Biotechnology
Department Manager of Clinical Medicine Departmen

TOP